title: Rap1 GTPase activation and barrier enhancement in rpe inhibits choroidal neovascularization in vivo.
abstract: Loss of barrier integrity precedes the development of pathologies such as metastasis, inflammatory disorders, and blood-retinal barrier breakdown present in neovascular age-related macular degeneration. Rap1 GTPase is involved in regulating both endothelial and epithelial cell junctions; the specific role of Rap1A vs. Rap1B isoforms is less clear. Compromise of retinal pigment epithelium barrier function is a contributing factor to the development of AMD. We utilized shRNA of Rap1 isoforms in cultured human retinal pigment epithelial cells, along with knockout mouse models to test the role of Rap1 on promoting RPE barrier properties, with emphasis on the dynamic junctional regulation that is triggered when the adhesion between cells is challenged. In vitro, Rap1A shRNA reduced steady-state barrier integrity, whereas Rap1B shRNA affected dynamic junctional responses. In a laser-induced choroidal neovascularization (CNV) model of macular degeneration, Rap1b(-/-) mice exhibited larger CNV volumes compared to wild-type or Rap1a(-/-) . In vivo, intravitreal injection of a cAMP analog (8CPT-2'-O-Me-cAMP) that is a known Rap1 activator significantly reduced laser-induced CNV volume, which correlated with the inhibition of CEC transmigration across 8CPT-2'O-Me-cAMP-treated RPE monolayers in vitro. Rap1 activation by 8CPT-2'-O-Me-cAMP treatment increased recruitment of junctional proteins and F-actin to cell-cell contacts, increasing both the linearity of junctions in vitro and in cells surrounding laser-induced lesions in vivo. We conclude that in vitro, Rap1A may be important for steady state barrier integrity, while Rap1B is involved more in dynamic junctional responses such as resistance to junctional disassembly induced by EGTA and reassembly of cell junctions following disruption. Furthermore, activation of Rap1 in vivo inhibited development of choroidal neovascular lesions in a laser-injury model. Our data suggest that targeting Rap1 isoforms in vivo with 8CPT-2'-O-Me-cAMP may be a viable pharmacological means to strengthen the RPE barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration.
authors.affiliation: Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
authors.forename: Erika S
authors.initials: ES
authors.lastname: Wittchen
authors.forename: Eiichi
authors.initials: E
authors.lastname: Nishimura
authors.forename: Manabu
authors.initials: M
authors.lastname: McCloskey
authors.forename: Haibo
authors.initials: H
authors.lastname: Wang
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Quilliam
authors.forename: Magdalena
authors.initials: M
authors.lastname: Chrzanowska-Wodnicka
authors.forename: M Elizabeth
authors.initials: ME
authors.lastname: Hartnett
mesh_terms: D000818:Animals; D001813:Blood-Retinal Barrier / Q000378:metabolism*; D020256:Choroidal Neovascularization / Q000235:genetics / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism / Q000494:pharmacology; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000378:metabolism; D004789:Enzyme Activation; D006801:Humans; D007365:Intercellular Junctions / Q000378:metabolism; D008268:Macular Degeneration / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D051379:Mice; D018345:Mice, Knockout; D057705:Transendothelial and Transepithelial Migration / Q000187:drug effects; D020827:rap1 GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D000242:Cyclic AMP; D020827:rap1 GTP-Binding Proteins
references.citation: Mol Cell Biol. 2006 Jan;26(2):643-53
references.pmid: 16382154
references.citation: Curr Opin Cell Biol. 2009 Oct;21(5):684-93
references.pmid: 19615876
references.citation: Mol Cell Biol. 2008 Sep;28(18):5803-10
references.pmid: 18625726
references.citation: Invest Ophthalmol Vis Sci. 2011 Jun 01;52(6):3880-7
references.pmid: 21296820
references.citation: PLoS Comput Biol. 2012;8(5):e1002440
references.pmid: 22570603
references.citation: Cell. 2004 Jan 23;116(2):167-79
references.pmid: 14744429
references.citation: Invest Ophthalmol Vis Sci. 2011 Sep 27;52(10):7455-63
references.pmid: 21873678
references.citation: N Engl J Med. 2011 May 19;364(20):1897-908
references.pmid: 21526923
references.citation: Blood. 2011 Aug 18;118(7):2015-26
references.pmid: 21636859
references.citation: Mol Cell Biol. 2005 Jan;25(1):136-46
references.pmid: 15601837
references.citation: Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1188-96
references.pmid: 18178724
references.citation: J Biol Chem. 2004 Aug 20;279(34):35127-32
references.pmid: 15166221
references.citation: Vascul Pharmacol. 2010 Jul-Aug;53(1-2):1-10
references.pmid: 20302970
references.citation: Exp Cell Res. 2007 Jul 1;313(11):2504-20
references.pmid: 17493609
references.citation: J Cell Biol. 2006 Oct 9;175(1):135-46
references.pmid: 17015620
references.citation: J Cell Biol. 2011 Oct 17;195(2):245-61
references.pmid: 22006950
references.citation: Small GTPases. 2011 Mar;2(2):65-76
references.pmid: 21776404
references.citation: Exp Eye Res. 2006 Dec;83(6):1325-34
references.pmid: 16959248
references.citation: Mol Cell Biol. 2007 Nov;27(22):7966-80
references.pmid: 17846121
references.citation: Biochim Biophys Acta. 2009 Apr;1788(4):790-6
references.pmid: 19159611
references.citation: J Appl Physiol (1985). 2009 Dec;107(6):1900-10
references.pmid: 19850733
references.citation: J Cell Biol. 2004 Oct 11;167(1):111-22
references.pmid: 15479739
references.citation: Mol Cell Biol. 2004 Aug;24(15):6690-700
references.pmid: 15254236
references.citation: Mol Vis. 2010 Sep 02;16:1781-90
references.pmid: 20824160
references.citation: Mol Biol Cell. 2009 Apr;20(7):1916-25
references.pmid: 19176753
references.citation: J Cell Physiol. 2011 Feb;226(2):414-23
references.pmid: 20672289
references.citation: Cytoskeleton (Hoboken). 2011 Jan;68(1):32-43
references.pmid: 20925106
references.citation: Assay Drug Dev Technol. 2004 Aug;2(4):363-72
references.pmid: 15357917
references.citation: PLoS One. 2011 Mar 11;6(3):e17841
references.pmid: 21412440
references.citation: Curr Eye Res. 2006 Sep;31(9):739-48
references.pmid: 16966147
references.citation: Blood. 2005 Mar 1;105(5):1950-5
references.pmid: 15374886
references.citation: Exp Eye Res. 2007 Apr;84(4):737-44
references.pmid: 17292356
references.citation: Ann N Y Acad Sci. 2012 Jul;1258:34-42
references.pmid: 22731713
references.citation: Invest Ophthalmol Vis Sci. 1986 Nov;27(11):1644-52
references.pmid: 2429937
references.citation: Curr Drug Targets. 2011 Feb;12(2):221-33
references.pmid: 20887239
references.citation: Angiogenesis. 2012 Jun;15(2):213-27
references.pmid: 22392094
references.citation: Exp Eye Res. 2006 Apr;82(4):608-19
references.pmid: 16259980
references.citation: Nature. 2004 Oct 7;431(7009):647-52
references.pmid: 15470418
references.citation: Mol Biol Cell. 2006 Feb;17(2):966-76
references.pmid: 16339077
references.citation: J Cell Biochem. 2008 Nov 1;105(4):1027-37
references.pmid: 18767072
references.citation: Exp Eye Res. 2004 Oct;79(4):543-51
references.pmid: 15381038
references.citation: FEBS Lett. 2005 Sep 12;579(22):4966-72
references.pmid: 16115630
references.citation: Nat Cell Biol. 2002 Nov;4(11):901-6
references.pmid: 12402047
references.citation: J Cell Biol. 1980 Dec;87(3 Pt 1):736-45
references.pmid: 6780571
references.citation: Science. 1998 Jan 23;279(5350):509-14
references.pmid: 9438836
references.citation: Physiology (Bethesda). 2010 Feb;25(1):16-26
references.pmid: 20134025
references.citation: Exp Cell Res. 1999 Nov 25;253(1):157-65
references.pmid: 10579920
references.citation: Dev Biol. 2012 Sep 15;369(2):223-34
references.pmid: 22776378
references.citation: Am J Pathol. 2007 Jul;171(1):53-67
references.pmid: 17591953
references.citation: Nat Cell Biol. 2003 Mar;5(3):236-41
references.pmid: 12598902
references.citation: Am J Pathol. 2010 Oct;177(4):2091-102
references.pmid: 20802176
references.citation: Arch Ophthalmol. 1997 Mar;115(3):345-50
references.pmid: 9076206
references.citation: Invest Ophthalmol Vis Sci. 2011 Apr 06;52(5):2165-9
references.pmid: 21471430
references.citation: Cardiovasc Res. 2010 Jul 15;87(2):243-53
references.pmid: 20299335
references.citation: J Cell Sci. 2006 May 15;119(Pt 10):2095-106
references.pmid: 16638813
references.citation: Invest Ophthalmol Vis Sci. 2011 Feb 01;52(1):570-8
references.pmid: 20811045
references.citation: Nature. 2009 Jul 9;460(7252):225-30
references.pmid: 19525930
references.citation: J Clin Invest. 2005 Mar;115(3):680-7
references.pmid: 15696195
references.citation: Circ Res. 2010 Jun 11;106(11):1731-42
references.pmid: 20413783
references.citation: Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18751-6
references.pmid: 19841260
references.citation: J Cell Physiol. 2008 Jun;215(3):715-24
references.pmid: 18064650
references.citation: Biochim Biophys Acta. 2008 Mar;1778(3):660-9
references.pmid: 17854762
references.citation: J Immunol. 2007 Dec 15;179(12):8322-31
references.pmid: 18056377
references.citation: Mol Biol Cell. 2010 Feb 15;21(4):584-96
references.pmid: 20032304
references.citation: J Am Soc Nephrol. 2011 May;22(5):859-72
references.pmid: 21493776
references.citation: J Biochem Mol Biol. 2006 Mar 31;39(2):132-9
references.pmid: 16584626
references.citation: Vascul Pharmacol. 2002 Nov;39(4-5):187-99
references.pmid: 12747959
references.citation: Blood. 2008 Mar 1;111(5):2647-56
references.pmid: 17993608
references.citation: Eye Brain. 2011;3:19-28
references.pmid: 27795668
references.citation: Mol Vis. 2008 Feb 11;14:345-57
references.pmid: 18334951
references.citation: Blood. 2009 Jan 8;113(2):488-97
references.pmid: 18805968
references.citation: Microvasc Res. 2010 Mar;79(2):128-38
references.pmid: 19962392
references.citation: Assay Drug Dev Technol. 2006 Oct;4(5):597-607
references.pmid: 17115930
references.citation: Prog Retin Eye Res. 2010 Nov;29(6):500-19
references.pmid: 20488255
references.citation: J Biol Chem. 2005 Mar 25;280(12):11675-82
references.pmid: 15661741